Glenn Saldanha does not believe that Glenmark has fallen silent on the licensing front. The next 12 to 18 months will see the company venture into out-licensing pacts with global partners to develop prospective drugs from the Glenmark stable, says Saldanha, ... Business Line, 4 days ago
2 images for "glenn saldanha"
Mukesh Ambani : $22.7 billion Dilip Shanghvi : $16.9 billion Hinduja Brothers : $15.2billion Azim Premji : $15billion Pallonji Mistry : $13.9billion Lakshmi mittal : $12.5billion Godrej Family : $12.4billion Shiv Nadar : ...ZeeNews.com, 1 day ago Hurun India Rich List 2016 Hurun Report, 2 weeks ago
The Indian government has been trying to push the oil-for-drugs barter plan for months now, similar to the one it worked out with Iran Hyderabad: India's oil-for-drugs barter plan with cash-strapped Venezuela to help recover millions of dollars in ...Livemint.com, 2 days ago
Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel Bispecific Monoclonal Antibody targeting EGFR
Posted On: 2016-09-19 20:20:03 Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), has announced the discovery and initiation of IND-enabling studies for a novel clinical development ...Equity Bulls, 4 days ago Glenmark announces discovery and initiation of clinical development of novel anti-cancer drug Livemint.com, 2 weeks ago Glenmark initiates IND-enabling studies targeting cancer Moneycontrol.com, 2 weeks ago Glenmark begins IND enabling studies of bispecific monoclonal antibody, GBR 1372 PharmaBiz, 2 weeks ago
More from: , Financial Express...and 1 other sources
from Wilson Shirva Raymond Pinto( 85) son of the late Piad Pinto and the late Angeline Pinto, husband of Cecillia pinto and father of Gilbert/ Agnes, Benedicta / Charles, Robert / Veena, Rony Nobert / Preethi, Albert/ Shobha, passed away on 30 ...Daijiworldcom, 3 weeks ago
Drug companies are expecting an uptick in domestic sales, following a muted quarter which saw business slow down due to price caps and government ban on fixed dose combination drugs. Domestic sales grew 6.4 per cent in April-June quarter in ...Business Standard India, 1 month ago Drug companies expect rebound in domestic business Business Standard India, 1 month ago
India's pharmaceutical sector grew at 6.4% in the April-June quarter, down from 14.8% last year, largely due to the aggressive price controls by the government Indian drug makers are now feeling the pinch of the drug price controls put in place by ...Livemint.com, 1 month ago
- Moneycontrol.com By The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing DirectorMoneycontrol.com, 1 month ago
Consolidated revenue was at Rs 19,430.52 million, recording an increase of 17.92 per cent Glenmark Pharmaceuticals, the research-led global integrated pharma company announced its results for the first quarter ended June 30, 2016. For the ...Express Pharma, 1 month ago Glenmark Q1 profit rises 24% to Rs.226.8 crore Livemint.com, 1 month ago Glenmark net up 24% at Rs 227 cr Hindu Business Line, 1 month ago Glenmark Pharmaceuticals net profit up 23.96% in Q1 Yahoo! India, 1 month ago
"The US business continues to perform well and the recent approvals for the business will ensure the growth momentum will continue. Europe business performed well due to strong growth witnessed by the UK subsidiary," Glenn Saldanha, chairman MD said.Money Control, 1 month ago
on your WebpageAdd Widget >Get your members hooked!